Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + pyrotinib + CapeOX first-line study in HER2-positive gastric cancer
ChiCTR2000029717Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, pyrotinib, capecitabine and oxaliplatin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Maximum tolerated dose and Progression-free survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
camrelizumabpyrotinibcapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000029717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029717.